Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Geisler, Benjamin P.; Zahabi, Lara El; Lang, Adam Edward; Eastwood, Naomi; Tennant, Elaine; Lukic, Ljiljana; Sharon, Elad; Chuang, Hai‐Hua; Kang, Chang-Berm; Clayton-Johnson, Knakita; Aljaberi, Ahmed; Yu, Haining; Bui, Chinh; Mau, Tuan Le; Li, Wencheng; Teodorescu, Debbie Lin; Hinske, Ludwig Christian; Sun, Dennis L.; Manian, Farrin A.; Dunn, Adam G.

doi:10.1101/2020.05.21.20109074

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the included patients, we reviewed prescription data, including systemic glucocorticoids (dexamethasone and other corticosteroids), ciclesonide, remdesivir, hydroxychloroquine, ivermectin, favipiravir, azithromycin, and statins, which were referred to as repurposed drugs used for anti-inflammatory or antiviral effects [25]. We additionally examined prescription records for anticoagulants and antiplatelets because some studies have shown that these drugs can modify the course of COVID-19 [26].…”

Section: Pharmacological Managementmentioning

confidence: 99%

Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database

Takeuchi

Inokuchi

Kimura

et al. 2023

ACE

View full text Add to dashboard Cite

BackgroundEpidemiological data are essential for developing strategies against the current coronavirus disease 2019 (COVID-19) pandemic. Data on COVID-19 epidemiology in Japan are limited owing to a focus on specific regions and patient groups, particularly in the early phase of the pandemic. MethodsWe investigated COVID-19 epidemiology in Japan in 2020 using a large nationwide multihospital database containing insurance claim records and medical records.Inclusion criteria were inpatient and outpatient referrals for COVID-19 in 2020. We analyzed demographic data, comorbidities, drug use, severe COVID-19 risk, and clinical course of hospitalized patients (including death). ResultsWe identified 11,868 COVID-19 cases from 56 institutions: 6,440 outpatients and 5,428 inpatients. Of the patients, 53.2% had comorbid conditions, the most common of which was tumor (22.1%), and 56.4% were classed as having a high risk of COVID-19. 4Pharmacological management patterns were generally consistent between the first and second half of 2020, except for glucocorticoid use. The use of unauthorized medications (hydroxychloroquine, ivermectin, and favipiravir) was infrequent. For hospitalized patients, the median length of stay was 10 days, and 2.4% of patients were admitted to intensive care units. Post-COVID-19 all-cause mortality, all-cause 30-day mortality, and in-hospital deaths were recorded for 7.9%, 5.4%, and 4.6% of patients, respectively.Patients with high-risk conditions had a lower survival probability. ConclusionsThis descriptive study of COVID-19 in 2020 identified differences in care across outpatient and inpatient settings and changes in care delivery as the pandemic progressed. These findings could inform strategies for future infectious disease pandemics.

show abstract

Section: Pharmacological Managementmentioning

confidence: 99%

Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database

Takeuchi

Inokuchi

Kimura

et al. 2023

ACE

View full text Add to dashboard Cite

show abstract

“…Living systematic reviews (LSRs) are an emerging type of systematic review that involves the continual search of the literature and incorporation of relevant new evidence, soon after it becomes available 2 . While many evidence synthesis groups are engaged in conducting LSRs or living network meta-analyses, others have developed living databases or living maps, including resources specific for COVID-19 literature [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal

et al. 2021

View full text Add to dashboard Cite

Background: While the PRISMA flow diagram is widely used for reporting standard systematic reviews (SRs), it was not designed for capturing the results of continual searches for studies in living systematic reviews (LSRs). The objectives of this study are (1) to assess how published LSRs report on the flow of studies through the different phases of the review for the different updates; (2) to propose an approach to reporting on that flow. Methods: For objective 1, we identified all LSRs published up to July 2020. We abstracted information regarding their general characteristics and how they reported on search results. For objective 2, we based our proposal for tailored PRISMA approaches on the findings from objective 1, as well as on our experience with conducting Cochrane LSRs. Results: We identified 108 living publications relating to 32 LSRs. Of the 108 publications, 7% were protocols, 24% were base versions (i.e., the first version), 62% were partial updates (i.e., does not include all typical sections of an SR), and 7% were full updates (i.e., includes all typical sections of an SR). We identified six ways to reporting the study flow: base separately, each update separately (38%); numbers not reported (32%); latest update separately, all previous versions combined (20%); base separately, all updates combined (7%); latest update version only (3%); all versions combined (0%). We propose recording in detail the results of the searches to keep track of all identified records. For structuring the flow diagram, we propose using one of four approaches. Conclusion: We identified six ways for reporting the study flow through the different phases of the review for the different update versions. We propose to document in detail the study flow for the different search updates and select one of our four tailored PRISMA diagram approaches to present that study flow.

show abstract

Section: Introductionmentioning

confidence: 99%

PRISMA flow diagrams for living systematic reviews: a methodological survey and a proposal

et al. 2021

View full text Add to dashboard Cite

Background: While the PRISMA flow diagram is widely used for reporting standard systematic reviews (SRs), it was not designed for capturing the results of continual searches for studies in living systematic reviews (LSRs). The objectives of this study are (1) to assess how published LSRs report on the flow of studies through the different phases of the review for the different updates; (2) to propose an approach to reporting on that flow. Methods: For objective 1, we identified all LSRs published up to July 2020. We abstracted information regarding their general characteristics and how they reported on search results. For objective 2, we based our proposal for tailored PRISMA approaches on the findings from objective 1, as well as on our experience with conducting Cochrane LSRs. Results: We identified 108 living publications relating to 32 LSRs. Of the 108 publications, 7% were protocols, 24% were base versions (i.e., the first version), 62% were partial updates (i.e., does not include all typical sections of an SR), and 7% were full updates (i.e., includes all typical sections of an SR). We identified six ways to reporting the study flow: base separately, each update separately (38%); numbers not reported (32%); latest update separately, all previous versions combined (20%); base separately, all updates combined (7%); latest update version only (3%); all versions combined (0%). We propose recording in detail the results of the searches to keep track of all identified records. For structuring the flow diagram, we propose using one of four approaches. Conclusion: We identified six ways for reporting the study flowthrough the different phases of the review for the different update versions. We propose to document in detail the study flow for the different search updates and select one of our four tailored PRISMA diagram approaches to present that study flow.

show abstract

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Cited by 4 publications

References 16 publications

Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database

Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database

Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal

PRISMA flow diagrams for living systematic reviews: a methodological survey and a proposal

Contact Info

Product

Resources

About